<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 15, 1996
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
New Jersey 1-1-432 22-2429994
- ------------------ ----------------- ---------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- -------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today that it has
agreed in principle to acquire a fully-equipped pharmaceutical manufacturing
facility from Searle Canada, a unit of Monsanto Canada Inc. Finalization of the
purchase is expected in early 1997.
The 100,852 square foot facility located in Oakville, Ontario is
approved by both the U.S. Food and Drug Administration and the Health Protection
Branch of Canada. In addition to manufacturing and packaging, the Oakville
facility includes laboratory (QC/QA), warehouse, and administrative space.
The transfer of product manufacturing from third-party manufacturers to
its own production facility is a natural evolution in Roberts growth and should,
in time, result in substantial cost savings through reduced cost of goods, lower
levels of inventory, and the integration of Roberts Pharmaceutical Canada from
its leased space in Mississauga, Ontario to the Oakville site.
Upon finalizing the purchase, Searle has agreed in principle to lease
back space for a time. Searle has also agreed in principle to have Roberts
fulfill certain of Searle's product packaging requirements which are currently
being met by the Oakville facility. Contract manufacturing by Roberts of other
Searle products may be negotiated prior to the transfer of the plant's
ownership. In addition, Roberts may consider contract manufacturing for other
pharmaceutical companies. Also, Roberts will examine the possibility of cost
savings that may arise from the potential consolidation of its distribution
channels for finished goods into the Oakville site.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: October 17, 1996 By: /s/ Anthony A. Rascio
-------------------------------
Anthony A. Rascio
Vice President
